C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 314—Applications for Fda Approval to Market A New DrugSubpart C—Abbreviated Applications

21 C.F.R. § 314.92 (2026)

Drug products for which abbreviated applications may be submitted

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1995–2024 19citing cases
At a glance

Courts have cited this section in 19 opinions since 1995, 4 of them in the last five years.

(a) Abbreviated applications are suitable for the following drug products within the limits set forth under § 314.93:

(1) Drug products that are the same as a listed drug. A “listed drug” is defined in § 314.3. For determining the suitability of an abbreviated new drug application, the term “same as” means identical in active ingredient(s), dosage form, strength, route of administration, and conditions of use, except that conditions of use for which approval cannot be granted because of exclusivity or an existing patent may be omitted. If a listed drug has been voluntarily withdrawn from or not offered for sale by its manufacturer, a person who wishes to submit an abbreviated new drug application for the drug shall comply with § 314.122.

(2) [Reserved]

(3) Drug products that have been declared suitable for an abbreviated new drug application submission by FDA through the petition procedures set forth under § 10.30 of this chapter and § 314.93.

(b) FDA will publish in the list listed drugs for which abbreviated applications may be submitted. The list is available from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402, 202-783-3238.

[57 FR 17983, Apr. 28, 1992, as amended at 64 FR 401, Jan. 5, 1999]
The 19 cases that cite 21 C.F.R. § 314.92 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENAstrazeneca LP v. Apotex, Inc., 633 F.3d 1042 (Fed. Cir. 2010).
cites § 314.92 2×cited by 121 cases
The case’s holding
A manufacturer induces infringement if a proposed label instructs users in a manner that would inevitably lead some consumers to practice the patented method.
Later courts cite it for
“the pertinent question is whether the proposed label instructs users to perform the patented method.” · 10 citing courts
2
GREENSerono Labs Inc v. Ferring Pharm. Inc., 158 F.3d 1313 (D.C. Cir. 1998).
cites § 314.92 2×cited by 292 cases
The case’s holding
Courts must defer to the agency's technical expertise when determining whether a generic drug is bioequivalent to a reference drug under the statutory sameness requirement.
Later courts cite it for
“these factors interrelate on a sliding scale and must be balanced against each other.” · 27 citing courts
3
GREENDorsett v. Sandoz, Inc., 699 F. Supp. 2d 1142 (C.D. Cal. 2010).
cites § 314.92 2×cited by 15 cases
Where it cites § 314.92
“See 21 C.F.R. § 314.92 (a)(1). “[T]he term ‘same as’ means identical in active ingredient(s), dosage form, strength, route of administration, and conditions of use.”
4
GREENFujisawa Pharm. Co. v. John K. Kapoor, 115 F.3d 1332 (7th Cir. 1997).
cites § 314.92 1×cited by 115 cases
Where it cites § 314.92
“§ 355®; 21 C.F.R. §§ 314.92 -.99. The abbreviation lies in the fact that, since the proprietary version had been approved upon a showing that it was safe and effective (the showing required for approval of an application for a new drug), the producer of the generic version need…”
The case’s holding
Facts constituting inquiry notice must be sufficiently probative of fraud (basis: inquiry notice requirement).
Later courts cite it for
“must be sufficiently probative of fraud-sufficiently advanced beyond the stage of a mere suspicion . . . to incite the victim to investigate.” · 7 citing courts
5
GREENRodney Guilbeau v. Pfizer Inc., 880 F.3d 304 (7th Cir. 2018).
cites § 314.92 1×cited by 13 cases
Where it cites § 314.92
“5 As Depo-T itself demonstrates, having a registered trademark name and being designated as an RLD does not change a drug’s approval process classification at FDA.”
Later courts cite it for
“an actual conflict between state and federal law such that it is impossible for a person to obey both.” · 3 citing courts
6
GREENEli Lilly & Co. v. Roussel Corp., 23 F. Supp. 2d 460 (D.N.J. 1998).
cites § 314.92 1×cited by 94 cases
Where it cites § 314.92
“21 C.F.R. § 314.92 (a). An applicant must file an Abbreviated Antibiotic Drug Application ("AADA”) which must demonstrate that the generic antibiotic will be bioequivalent to the innovator drug and will be manufactured and marketed in accordance with approved practices and…”
The case’s holding
A plaintiff must identify specific, clear representations in advertising to state a claim under Section 43(a) of the Lanham Act because a mere failure to disclose facts is not actionable.
Later courts cite it for
“it is the plaintiff's (as opposed to a third party's) conferral of a benefit on defendant which forms the basis of an unjust enrichment claim.” · 16 citing courts
7
GREENMylan Pharm., Inc. v. Thompson, 139 F. Supp. 2d 1 (D.D.C. 2001).
cites § 314.92 1×cited by 20 cases
Where it cites § 314.92
“§§ 355 (j)(2)(A)(iii), (j)(4)(D)(i)-(ii); see also 21 C.F.R. § 314.92 (a)(1) (1999) (indicating the categories of drug products for which an ANDA may be filed).”
8
YELLOWMensing v. Wyeth, Inc., 562 F. Supp. 2d 1056 (D. Minn. 2008).
cites § 314.92 1×cited by 17 cases
Flagged on editorial review. Overruled by Mensing v. Wyeth, Inc.
Where it cites § 314.92
“§ 3550 )(1); 21 C.F.R. § 314.92 (a). The manufacturer of a generic drug must show that the generic drug has the same active ingredients and is the “bioequivalent” of the listed drug.”
Later courts cite it for
“is no longer consistent with that for the listed drug,” · 2 citing courts
9
GREENTakeda Pharm. USA, Inc. v. West-Ward Pharm. Corp., 72 F. Supp. 3d 539 (D. Del. 2014).
cites § 314.92 1×cited by 6 cases
Where it cites § 314.92
“3d at 1046 ; 21 C.F.R. § 314.92 (a)(1). . 35 U.S.C. § 271 (e)(2)(A) provides that "[i]t shall be an act of infringement to submit” an ANDA "for a drug claimed in a patent or the use of which is claimed in a patent.”
10
GREENSerono Labs., Inc. v. Shalala, 974 F. Supp. 29 (D.D.C. 1997).
cites § 314.92 2×cited by 3 cases
Where it cites § 314.92
“” 21 C.F.R. § 314.92 (a)(1). The Hatch-Waxman Amendments also require that an ANDA applicant demonstrate that a generic drug, is not unsafe “because of the type or quantity of inactive ingredients included .”
11
REDPfizer Inc. v. Shalala, 1 F. Supp. 2d 38 (D.D.C. 1998).
cites § 314.92 2×cited by 3 cases
Reversed in part by Pfizer Inc v. Shalala, Donna E. (1999): the Court of Appeals for the D.C. Circuit's own opinion in this case ("*981 The judgment of the district court is therefore Affirmed in part and reversed in part.").
Where it cites § 314.92
“§ 355 (j)(2)(A)(iii)), and despite the FDA’s own regulations interpreting this provision to require an “identical” dosage form ( 21 C.F.R. § 314.92 (a)(1)), the FDA in fact accepts ANDAs for review without first approving a suitability petition when the dosage form is not the…”
12
GREENBristol-Myers Squibb Co. v. Shalala, 892 F. Supp. 295 (D.D.C. 1995).
cites § 314.92 4×cited by 1 case
Where it cites § 314.92
“” 21 C.F.R. § 314.92 (a)(2). Under the abbreviated procedure, a generic manufacturer is not required to produce the results of clinical testing as long as the finished product satisfies the standards contained in the monograph for the pioneer version of the finished product.”
13
GREENWarner Lambert Co v. Shalala, Donna E., 202 F.3d 326 (D.C. Cir. 2000).
cites § 314.92 1×cited by 4 cases
Where it cites § 314.92
“§ 355(j)(2)(A)(ii)-(iv), (j)(4); see also 21 CFR § 314.92 (a)(1) (1999) (indicating the categories of drug products for which ANDAs may be filed).”
Later courts cite it for
“full reports of investigations which have been made to show whether or not such drug is safe for use and whether such drug is effective in use.” · 2 citing courts
14
GREENStat-Trade Inc. v. U.S. Food & Drug Admin., 869 F. Supp. 2d 95 (D.D.C. 2012).
cites § 314.92 1×cited by 1 case
Where it cites § 314.92
“” 21 C.F.R. § 314.92 (a)(1) (1999). 13 . The Congressional Record establishes that H.”
15
NO FLAGNovartis Pharm. Corp. v. Becerra, No. 2024-2234 (D.D.C. Oct. 15, 2024).
cites § 314.92 3×cited by 0 cases
Summary
No passage or summary on file for this case yet.
16
GREENTeva Pharm. USA, Inc. v. United States Food & Drug Admin., 514 F. Supp. 3d 66 (D.D.C. 2020).
cites § 314.92 2×cited by 0 cases
Where it cites § 314.92
“§ 355(j)(2)(A) (ii), (iii), a standard that requires the generic drug to be “identical in active ingredient(s), dosage form, strength, route of administration, and conditions of use,” 21 C.F.R. § 314.92 (a)(1). The applicant 3 must also establish that the proposed generic is…”
Later courts cite it for
“ordinary meaning is of limited utility . . . when determining the proper interpretation of a technical term.” · 2 citing courts
17
GREENGlaxosmithkline LLC v. Teva Pharm. USA, Inc., 7 F.4th 1320 (Fed. Cir. 2021).
cites § 314.92 2×cited by 0 cases
Where it cites § 314.92
“94 (a)(7)(i); see also 21 C.F.R. § 314.92 (a) (noting that, with limited Case: 18-1976 Document: 187 Page: 63 Filed: 08/05/2021 GLAXOSMITHKLINE LLC v.”
Later courts cite it for
“a generic may not rely upon the orange book use codes provided by the brand for patent infringement purposes.” · 2 citing courts
18
GREENFresenius Kabi USA LLC v. Par Sterile Prods. LLC, 841 F. App'x 399 (3d Cir. 2021).
cites § 314.92 1×cited by 0 casesunpublished
Where it cites § 314.92
“§ 355 (j); 21 C.F.R. § 314.92 . Both applications must contain descriptions of the drug’s chemical makeup, including its active pharmaceutical ingredient (“API”).”
19
NO FLAGVanda Pharm. Inc. v. Food & Drug Admin., No. 2023-2812 (D.D.C. Sept. 10, 2024).
cites § 314.92 1×cited by 0 cases
Where it cites § 314.92
“§ 355 (j)(2)(A)(ii), (iii), meaning the generic drug must be “identical in active ingredient(s), dosage form, strength, route of administration, and conditions of use,” 21 C.F.R. § 314.92 (a)(1). Relevant here, the applicant must also establish that its generic drug is…”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199520092024

One bar per year. Tallest: 3 cases in 1998. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.D.C.87th Cir.2D.C. Cir.2Fed. Cir.23rd Cir.1C.D. Cal.1D. Del.1D. Minn.1

The 8 courts with the most citing cases, of 9 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com